Patent · US Active

Anti-KIR3DL1 antibodies

US11117964B2 · kind B2 · utility

4Cited by

9References

20Claims

0Family size

Assignees

Memorial Sloan Kettering Cancer Center · US
Eureka Therapeutics, Inc. · US

Inventors

Katharine Hsu · New York, US
Nai-Kong V. Cheung · New York, US
Su Yan · Tangxia, CN
Yiyang Xu · Pleasanton, US
Jingyi Xiang · Walnut Creek, US
Cheng Liu · Richmond, US

Key dates

Filing date	Feb 26, 2018
Grant date	Sep 14, 2021
Priority date	—
Expiry date	Jun 22, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides antibody agents that bind to inhibitory human killer immunoglobulin-like receptors (KIRs). Particular antibody agents of the disclosure include antibody agents that bind to KIR3DL1 (also known as CD158e). Also provided are related nucleic acids, vectors, compositions and methods of using KIR-binding antibody agents of the present technology.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.